Ionis Pharmaceuticals financials
$44.65−2.70%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $943.7M | $705.1M | $787.6M | $587.4M | $810.5M | $729.3M | $1.12B | $599.7M | $514.2M | $372.8M |
| Gross profit | $927.8M | $693.9M | $778.5M | $573.3M | $799.6M | $717.3M | $1.12B | $597.9M | $139.5M | $28.5M |
| Gross margin | 98.3% | 98.4% | 98.8% | 97.6% | 98.7% | 98.4% | 99.6% | 99.7% | 27.1% | 7.6% |
| Operating income | -$381.7M | -$475.1M | -$353.7M | -$410.2M | -$30.2M | -$172.1M | $365.9M | -$61.4M | $31.0M | -$20.2M |
| Net income | -$381.4M | -$453.9M | -$366.3M | -$269.7M | -$28.6M | -$444.3M | $278.1M | $273.7M | $18.8K | -$60.4M |
| Net margin | −40.4% | −64.4% | −46.5% | −45.9% | −3.5% | −60.9% | 24.8% | 45.6% | 0.0% | −16.2% |
| Diluted EPS | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 | $-3.18 | $1.90 | $2.07 | $0.15 | $-0.50 |
| EBITDA | -$371.7M | -$465.5M | -$343.4M | -$393.4M | -$10.6M | -$154.9M | $380.3M | -$48.8M | $43.1M | -$4.4M |
| Operating cash flow | -$268.6M | -$500.9M | -$307.5M | -$274.4M | $30.8M | $35.9M | $345.6M | $602.9M | $174.1M | -$112.1M |
| Free cash flow | -$320.0M | -$546.2M | -$331.3M | -$290.1M | $18.8M | $772.0K | $314.7M | $585.3M | $136.3M | -$123.6M |
| Diluted shares | 160.0M | 149.5M | 143.2M | 141.8M | 141.0M | 139.6M | 153.2M | 134.1M | 0.1M | 120.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $372.3M | $242.1M | $399.3M | $276.5M | $869.2M | $397.7M |
| Short-term investments | $2.31B | $2.06B | $1.93B | $1.71B | $1.25B | $1.49B |
| Total debt | $1.75B | $1.25B | $1.27B | $1.18B | $1.22B | $908.9M |
| Total assets | $3.52B | $3.00B | $2.99B | $2.53B | $2.61B | $2.39B |
| Total liabilities | $3.03B | $2.42B | $2.60B | $1.96B | $1.84B | $1.65B |
| Shareholders' equity | $489.1M | $588.4M | $386.7M | $572.9M | $771.7M | $743.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology